# A Phase II Trial of Cabozantinib With Patients With Refractory GCTs

> **NCT04876456** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Jennifer King** · enrollment: 50 (estimated)

## Conditions studied

- Germ Cell Tumor
- Seminoma
- Non-seminomatous Germ Cell Tumor
- Ovarian Germ Cell Tumor

## Interventions

- **DRUG:** Cabozantinib

## Key facts

- **NCT ID:** NCT04876456
- **Lead sponsor:** Jennifer King
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-06-10
- **Primary completion:** 2027-01
- **Final completion:** 2027-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-01-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04876456

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04876456, "A Phase II Trial of Cabozantinib With Patients With Refractory GCTs". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04876456. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*